Nimbus Health GmbH

Executive Summary

Nimbus Health is a licensed German medical cannabis pharmaceutical wholesaler operating in the right market at the right time — Germany's post-MedCanG regulatory unlock has driven a 3,300% prescription surge and the market is on a credible trajectory to EUR 1B+ by 2028. The business itself has genuine institutional validation: it was acquired by Dr. Reddy's Laboratories (NYSE: RDY) in February 2022, signed multiple international distribution partnerships through early 2026, and holds the full stack of German pharmaceutical licences required to operate in this space. However, the single biggest structural concern is one that cannot be ignored: Nimbus Health appears to be a subsidiary of a publicly listed multinational pharmaceutical company, and the investor-facing materials present only three mid-level sales employees with no founders, C-suite, or regulatory leadership disclosed — a presentation gap that raises serious questions about ownership structure, governance, and the nature of any proposed investment. Before any capital is deployed, investors must establish unambiguously whether Nimbus Health is independently investable or whether this is a Dr. Reddy's subsidiary soliciting outside investment without parent company transparency.